Small Biotech Innovation Act
- Bill Number
- H.R. 3731
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-04: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2026-04-15T08:06:17Z
AI-Generated Summary
Purpose of the Legislation
The "Small Biotech Innovation Act" (H.R. 3731) aims to protect small biotechnology companies that heavily invest in research and development (R&D) from mandatory price negotiations under Medicare's drug pricing program. By creating an exception, it seeks to encourage innovation in drug development without the financial pressures of negotiated lower prices for certain drugs.
Key Provisions
- Exception from Price Negotiation: Starting in 2029, certain drugs produced by qualifying small biotech manufacturers are exempt from being classified as "negotiation eligible drugs" under Medicare. This applies to "qualifying single source drugs" (drugs with no generic or biosimilar competition).
- Definition of Small Biotech Manufacturer:
- A company with 5 or fewer qualifying single source drugs.
- Must not be owned, controlled, or directed by a foreign government, or organized under the laws of a "covered nation" (as defined in U.S. law, typically referring to countries like China that pose national security risks).
- Research and Development-Intensive Requirement:
- The company must invest a minimum percentage of its average net revenue from the prior three years in R&D, based on the number of its qualifying drugs:
- 30% for 1 drug.
- 40% for 2 drugs.
- 50% for 3 drugs.
- 60% for 4 drugs.
- 70% for 5 drugs.
- R&D investments are measured using standard accounting rules (generally accepted accounting principles).
- Application Process: Manufacturers must submit an annual application to the Secretary of Health and Human Services (HHS) before each applicable year, including:
- Details on net product revenue and R&D spending.
- A certification of accuracy.
- Any additional information requested by HHS.
- Acquisition Rule: If a qualifying manufacturer is acquired after 2029 by a larger company that does not meet the criteria, the exception ends for that drug at the start of the next plan year.
- Dispute Resolution: Manufacturers can appeal HHS decisions denying their status through a formal process, which must conclude before the public announcement of selected drugs for negotiation.
Significant Changes to Existing Law
- Amends Section 1192(d)(2) of the Social Security Act, which defines drugs subject to Medicare's price negotiation program (established by the Inflation Reduction Act of 2022).
- Introduces a new category of exemption specifically for small, R&D-focused biotech firms, expanding the list of drugs that avoid negotiation. Previously, exemptions were limited to categories like low-spend drugs or treatments for multiple diseases; this adds a targeted carve-out based on company size, investment levels, and foreign ownership restrictions.
Potential Impacts
- On Government Agencies: HHS will need to review applications, verify data, and handle appeals, potentially increasing administrative workload and costs for implementing the exception.
- On Citizens: Medicare beneficiaries may face higher drug prices for exempted biotech products in the short term, but the law could foster long-term innovation, leading to new treatments. It might indirectly affect overall healthcare costs if more drugs enter the market without negotiation pressures.
- On International Relations: The foreign ownership restrictions could limit participation by companies tied to certain nations, potentially straining trade relations with those countries while bolstering U.S. national security in biotech.
Main Stakeholders Affected
- Small Biotech Manufacturers: Primary beneficiaries, gaining protection for their drugs to reinvest in R&D without negotiation risks.
- Larger Pharmaceutical Companies: May face competitive disadvantages if they acquire small biotechs, as exemptions could be lost post-acquisition.
- Medicare and HHS: Responsible for oversight, applications, and enforcement, impacting program administration.
- Patients and Healthcare Providers: Could see varied access to innovative drugs, depending on how exemptions influence pricing and development.
- U.S. Taxpayers: Potential effects on federal healthcare spending, as exempted drugs might not benefit from negotiated savings.
Notable Legal, Constitutional, or Political Implications
- Legal: Introduces verification requirements for R&D spending and ownership, which could lead to challenges over data accuracy or HHS's interpretive authority. The appeal process ensures due process (a constitutional right to fair hearings), but disputes must resolve quickly to align with Medicare timelines.
- Constitutional: No direct challenges apparent, but foreign ownership bans tie into national security laws, potentially invoking equal protection concerns if applied unevenly.
- Political: Highlights tensions in drug pricing debates—supporting innovation for small firms versus broader cost controls for Medicare. It could influence future pharma policy by setting precedents for industry-specific exemptions, amid ongoing discussions on balancing affordability and R&D incentives.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Pfluger, August [R-TX-11]
Cosponsors (3)
Rep. Kustoff, David [R-TN-8], Rep. Tenney, Claudia [R-NY-24], Rep. Simon, Lateefah [D-CA-12]
Recent Actions
- 2025-06-04: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-06-04: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-06-04: Introduced in House
- 2025-06-04: Introduced in House
Bill Versions
- Small Biotech Innovation Act — issued 2025-06-04 — PDF (6 pages)